Patents Assigned to Acceleron Pharma Inc.
  • Isolated nucleotide sequences encoding GDF traps
    Patent number: 9932379
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 3, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • BMPRII POLYPEPTIDES AND USES THEREOF
    Publication number: 20180086806
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands including BMP10, BMP15, activin B and BMP9 and may be used to treat fibrotic and angiogenic disorders.
    Type: Application
    Filed: April 5, 2017
    Publication date: March 29, 2018
    Applicant: Acceleron Pharma, Inc.
    Inventors: Ravindra Kumar, John Knopf
  • Follistatin fusion proteins and uses thereof
    Patent number: 9919030
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with a follistatin antagonist and methods for managing patients treated with a follistatin antagonist.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: March 20, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventor: Matthew L. Sherman
  • BMP-ALK3 antagonists and uses for promoting bone growth
    Patent number: 9914762
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density and strength. In certain embodiments, the present invention provides ALK3 polypeptides, including ALK3-Fc fusion proteins.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: March 13, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventor: Jasbir Seehra
  • Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
    Patent number: 9884900
    Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: February 6, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
    Patent number: 9850298
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: December 26, 2017
    Assignee: ACCELERON PHARMA INC.
    Inventor: Kenneth M. Attie
  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING ANEMIA
    Publication number: 20170360887
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Application
    Filed: December 3, 2015
    Publication date: December 21, 2017
    Applicants: Celgene Corporation, Acceleron Pharma Inc.
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
  • METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS
    Publication number: 20170327800
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Applicants: Acceleron Pharma Inc., Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Methods for increasing red blood cell levels comprising administering BMP9
    Patent number: 9809636
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 7, 2017
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • ALK7 Binding Proteins and Uses Thereof
    Publication number: 20170306028
    Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
    Type: Application
    Filed: April 21, 2017
    Publication date: October 26, 2017
    Applicants: Acceleron Pharma Inc., Adimab, LLC
    Inventors: John KNOPF, Jonathan BELK, Nathan J. SHARKEY, Ravindra KUMAR, Asya GRINBERG, Dianne SAKO, Roselyne CASTONGUAY, Yossi DAGON
  • Methods for increasing thermogenic adipocytes
    Patent number: 9790284
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 17, 2017
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • BMPRII POLYPEPTIDES AND USES THEREOF
    Publication number: 20170291933
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type II (BMPRII) polypeptide binds to ligands including BMP10, BMP15, activin B and BMP9 and may be used to treat fibrotic and angiogenic disorders.
    Type: Application
    Filed: April 5, 2017
    Publication date: October 12, 2017
    Applicant: Acceleron Pharma, Inc.
    Inventors: Ravindra Kumar, John Knopf
  • Activin Type 2 Receptor Binding Proteins and Uses Thereof
    Publication number: 20170281711
    Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
    Type: Application
    Filed: March 10, 2017
    Publication date: October 5, 2017
    Applicants: Acceleron Pharma Inc., Adimab, LLC
    Inventors: Ravindra KUMAR, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
  • Method for decreasing the body fat content in a subject by administering an ActRIIB protein
    Patent number: 9745559
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: August 29, 2017
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Ravindra Kumar
  • USE OF ACTIVIN RECEPTOR-LIKE KINASE 1 (ALK-1) ANTAGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20170152490
    Abstract: Some aspects of this disclosure provide methods and compositions for the treatment of cancer, for example, head and neck cancer, in a subject using ALK1 inhibitors, e.g., ALK1-ECD polypeptides, ALK1-Fc fusion proteins, or ALK1-inhibitory antibodies. In some embodiments, methods and compositions are provided for treating certain cancers with ALK1 inhibitors in combination with a chemotherapeutic platinum agent. In some embodiments, methods are provided for identifying whether a cancer in a subject will react to treatment with an ALK1 antagonist, either alone or in combination with a chemotherapeutic platinum agent, for example, based on a determination that the cancer or the subject is positive for human papilloma virus.
    Type: Application
    Filed: March 27, 2015
    Publication date: June 1, 2017
    Applicant: Acceleron Pharma, Inc.
    Inventors: Marat B. Alimzhanov, Shuchi Sumant Pandya
  • Polynucleotides encoding an actriib antibody
    Patent number: 9624301
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: April 18, 2017
    Assignees: Acceleron Pharma Inc., Dyax Corp.
    Inventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
  • ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
    Patent number: 9617319
    Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: April 11, 2017
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Jennifer Lachey
  • Activin-actriia antagonists and uses for treating multiple myeloma
    Patent number: 9572865
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: February 21, 2017
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Activin-actriia antagonists and uses for treating or preventing breast cancer
    Patent number: 9526759
    Abstract: In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: December 27, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Use of GDF traps to treat anemia
    Patent number: 9505813
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: November 29, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar